Antibacterial Compounds Targeting ATP Synthase
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for tuberculosis are lengthy, require multiple drugs, and are ineffective against multi-drug-resistant strains and latent infections, posing challenges in compliance and the rising tide of antibiotic resistance.
Innovation Solution
Development of novel compounds that interfere with ATP synthase in Mycobacterium tuberculosis, primarily inhibiting cytochrome bc1 activity, offering a new mechanism of action against TB, including resistant strains and latent infections.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current tuberculosis treatment regimens are used, then treatment effectiveness against standard strains is maintained, but treatment duration is lengthy (6-24 months) and requires multiple drugs
Solution Approach 1:
The patent extracts and targets a specific essential function of Mycobacterium tuberculosis - the cytochrome bc1 complex in the electron transport chain - with highly selective inhibitors. By focusing on this single critical target rather than using broad-spectrum multi-drug regimens, the invention aims to achieve effective treatment with fewer agents and potentially shorter duration while maintaining reliability against both standard and resistant strains
Solution Approach 2:
The patent employs parameter changes by developing compounds with optimized molecular structures (specific chemical formulas and substitutions) that enhance binding affinity and selectivity for the cytochrome bc1 complex. This allows for more potent inhibition at lower concentrations, potentially reducing treatment duration and improving effectiveness against resistant strains while maintaining activity against standard strains
2Reliability
If current tuberculosis treatment regimens are used, then standard strains are treated effectively, but multi-drug-resistant strains cannot be adequately treated
Solution Approach 1:
The patent designs cytochrome bc1 inhibitors with a new mechanism of action that is universally effective across different Mycobacterium tuberculosis strains, including both standard and multi-drug-resistant strains. By targeting an essential conserved function (electron transport via cytochrome bc1) rather than strain-specific targets, the compounds achieve broad-spectrum activity and adaptability against diverse bacterial populations
Solution Approach 2:
The patent uses the cytochrome bc1 complex as an intermediary target - a conserved essential component of the electron transport chain that mediates ATP production in all M. tuberculosis strains. By inhibiting this intermediary function, the compounds can effectively treat both standard and resistant strains, as the target is essential for bacterial survival regardless of resistance status to other antibiotics
3Productivity
If current tuberculosis treatment regimens are used, then bacterial burden is reduced in the intensive phase, but persisting bacilli require prolonged continuation phase to eliminate
Solution Approach 1:
The patent aims to achieve continuous useful action by developing compounds that maintain effective concentrations and sustained inhibition of the cytochrome bc1 complex throughout the treatment period. The long-acting nature of the inhibitors and their ability to penetrate into persistent bacterial populations allow for continuous bactericidal and sterilizing activity, potentially shortening both the intensive and continuation phases while ensuring complete elimination of persisting bacilli
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds potentially shorten treatment duration, improve patient compliance, and demonstrate activity against both replicating and non-replicating bacteria, including multi-drug-resistant TB strains, addressing the limitations of existing therapies.
Implementation Method 1
Such compounds may work by interfering with ATP synthase in M. tuberculosis, with the inhibition of cytochrome bc1 activity as the primary mode of action
Data Source
AI summary
The present invention relates to the following compoundswherein the integers are as defined in the description, and where the compounds may be useful as medicaments, for instance for use in the treatment of tuberculosis.